Drug intelligence / Profile preview

ODM-215

Development stage: Preclinical
Lead developer: Orion
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

ODM-215 is an investigational CAR-T cell therapy developed by Orion for the treatment of cancer, specifically within the field of immuno-oncology. It is a biologic (large molecule) therapy originating from Orion’s internal research and represents a novel approach in oncology, leveraging chimeric antigen receptor T-cell technology to target malignant cells. As of mid-2025, ODM-215 remains in preclinical development with plans to initiate phase I clinical trials within 12 to 24 months[1][2][3].

Beyond the preview

Go deeper on ODM-215.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ODM-215.

Explore the full profile